Coronavirus disease 2019 and viral hepatitis coinfection: Provide guidelines for integrated screening and treatment
- 15 May 2020
- journal article
- editorial
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (10), 1703-1704
- https://doi.org/10.1002/jmv.26021
Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2, the virus, that causes Coronavirus disease 2019 (COVID‐19) threatens global health. Emerging evidence and past experience from other coronaviruses suggests that people with underlying liver disease including viral hepatitis could be at risk of disease severity and mortality. However, with the present relatively low screening rates for the most prevalent viral hepatitis – Hepatitis B and C, many COVID‐19 cases especially in low middle income countries are unlikely to be screened for viral hepatitis coinfection. Without active screening, little will be known about the clinical and epidemiological manifestations which could negatively impact public health efforts. In this commentary, we call for systematic and integrated screening of Hepatitis B and C for COVID‐19 confirmed patients. We also call for guidelines for management and treatment as well as research to understand the epidemiology of coinfectionThis publication has 6 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- COVID-19: Abnormal liver function testsJournal of Hepatology, 2020
- Liver injury during highly pathogenic human coronavirus infectionsLiver International, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Liver injury in COVID-19: management and challengesThe Lancet Gastroenterology & Hepatology, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020